Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Snowdon has been awarded a new three-year contract from the Department of Defense (DoD) Program, Transformational Medical Technologies (TMT) for the discovery and preclinical development of novel medical treatments to combat biowarfare pathogens.
Subscribe to our email newsletter
Snowdon is a biopharmaceutical company that specialises in the discovery and development of novel small-molecule therapeutics for the treatment of pain, infectious diseases and nervous system disorders
Snowdon may receive up to $8.2m in support of development efforts under this new Defense Threat Reduction Agency (DTRA) contract.
The company is partnering with two centers of excellence at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School (UMDNJ-NJMS).
The Center for Emerging Pathogens in the Department of Medicine, under the direction of Nancy Connell, will test Snowdon’s drug candidates on specific biowarfare pathogens.